Global Albumin (as Excipient) Market Growth 2025-2031

Global Albumin (as Excipient) Market Growth 2025-2031

The global Albumin (as Excipient) market size is predicted to grow from US$ 4776 million in 2025 to US$ 6901 million in 2031; it is expected to grow at a CAGR of 6.3% from 2025 to 2031.

Albumin is a water-soluble globular protein produced in the liver. It accounts for 50% of blood plasma proteins. These play a vital role in regulating blood volume and act as transporters for molecules such as few hormones, bile salts, and ions. Albumin is commonly used as blood volumizer in rare diseases, burns, shocks, liver conditions, and other blood loss trauma and surgeries.

The industry"s leading manufacturers are Grifols, CSL and Takeda, which accounted for 20.39%, 15.19% and 14.36% of global revenues in 2019.

By region, Asia-Pacific is the largest consumption market of Albumin (as Excipient), with its sales volume at 70.83%.

LP Information, Inc. (LPI) ' newest research report, the “Albumin (as Excipient) Industry Forecast” looks at past sales and reviews total world Albumin (as Excipient) sales in 2024, providing a comprehensive analysis by region and market sector of projected Albumin (as Excipient) sales for 2025 through 2031. With Albumin (as Excipient) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Albumin (as Excipient) industry.

This Insight Report provides a comprehensive analysis of the global Albumin (as Excipient) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Albumin (as Excipient) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Albumin (as Excipient) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Albumin (as Excipient) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Albumin (as Excipient).

This report presents a comprehensive overview, market shares, and growth opportunities of Albumin (as Excipient) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Human Serum Albumin
Recombinant Albumin

Segmentation by Application:
Cell Culture Media
Medical Supplements
Therapeutics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
CSL
Grifols
Takeda
Octapharma
Hualan Bio
CBPO
Shanghai RAAS
Kedrion
LFB Group
Albumedix
Biotest
Merck
Ventria (InVitria)
HiMedia

Key Questions Addressed in this Report

What is the 10-year outlook for the global Albumin (as Excipient) market?

What factors are driving Albumin (as Excipient) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Albumin (as Excipient) market opportunities vary by end market size?

How does Albumin (as Excipient) break out by Type, by Application?